According to new study conducted by US federal on rats, mobile phone radiation did increase rats' brain tumors in males. It raises concerns as smartphone is being used so much by so many people on a daily basis and they are always carried along with each person during the day.
The study targeted rodents that were given doses of radiation every day for two years. Results produced were released on Friday that showed many male and female rodents developed brain and heart tumor after the experiment.
“Both the House and Senate have now spoken on the importance of expanding federal research into brain cancer,” said Elizabeth WILSon, president and CEO, American Brain Tumor Association. “We are grateful to Senator Ed Markey (D-MA) for making this request, and we also thank the Senate Appropriations Committee for listening to our community and including this in their annual defense spending bill.”
A new Neurology study investigated genes in the immune system and identified eight immune genes that may be linked to patients’ length of survival after developing the cancer.
A study using nanotechnology to treat brain tumors got such good results, the researchers initially questioned themselves. But further testing showed the results held up.
Researchers at the University of Miami, Florida International University and Nichols Children's studying ways to pierce the blood-brain barrier to treat brain tumors.
Proton beam therapy works differently from conventional radiation treatments, which rely on X-rays. Birusingh was the first patient to undergo the treatment— which uses a three-story, 200,000 pound machine— at the hospital.
Researchers have studied possible causes behind the development of brain tumors. The results show differences in expression of certain molecules known as metabolites when comparing healthy individuals with people who would eventually develop brain tumors. The greatest difference were found when looking at vitamin E.
The process would use a re-engineered polio virus, injecting it directly into the brain. The polio attacked the tumor, first causing it to swell, then awakening the immune system to attack the tumor.
National Brain Tumor Society dedicated to the brain tumor community, together with Oligo Nation, a community-driven non-profit dedicated to funding translational oligodendroglioma research, today announced $250,000 in grant-funding for a preclinical research study of an immunotherapeutic approach to oligodendroglioma treatment.
Researchers have shown previously that the therapeutic ketogenic diet (KD) prolongs survival in mouse models of glioma, explained by both direct tumor growth inhibition and suppression of pro-inflammatory microenvironment conditions. The aim of this study is to assess the effects of the KD on the glioma reactive immune response.
A team from the International School for Advanced Studies (SISSA) in Trieste has obtained very promising results by applying gene therapy to glioblastoma. Tests in vitro and in vivo on mice provided very clear-cut results, and modelling demonstrates that the treatment targets at least six different points of tumour metabolism.
A bold experiment to kill a vicious form of brain cancer has been granted breakthrough status by the Food and Drug Administration. Results in the earliest stage of testing have been so remarkable, the FDA wants to fast track the treatment to speed it to market.
The electrodes, battery pack and knit cap are the outward signs of Ledesma’s treatment. Attached to his head are 36 ceramic electrodes, which are attached to a battery pack that emits electrical impulses.
New technologies have been developed to improve the efficacy of treating a wider range of tumors, especially in delicate locations like the brain. The progressive cancer care and imaging center was among the first to deliver an emerging form of advanced radiation therapy called stereotactic radiosurgery (SRS). Now known as the Veterinary Radiosurgery and Imaging Center (VRIC), the leading-edge practice is part of a national network of cancer care centers operated by PetCure Oncology.
The blood-brain barrier is a natural defense system that prevents harmful substances in the blood from entering the brain. Doctors may have found a way to get past the barrier to treat cancer patients which may allow them to deliver chemotherapy drugs directly into the brain.
Scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients.
We’ve heard it a gazillion times that cell phone use can cause tumor in brain. But fret not all you mobile phone users out there, there is no link between mobile phone use and brain cancer, reveals a new, long-running study.
Removing every last cancer cell or killing them all with radiation is at best a hit-and-miss solution. Fewer than 10% of those who are afflicted with gliomas live five years. Therefore, news from scientists in Belgium working with mice and using cancer vaccines against gliomas is encouraging, if not remarkable.
The fight against deadly forms of brain cancer, such as glioblastoma, could soon benefit from a major breakthrough, thanks to A*STAR researchers. The team has found a new link between cancer cell growth and its microenvironment.
Neurosurgeons using lasers to treat brain cancer have discovered that the technique breaks down the blood-brain barrier. The blood-brain barrier is sort of a natural "security system" that shields the brain from toxins in the blood but also blocks potentially helpful drugs such as those used in chemotherapy.
Oncurious in Leuven (Belgium) was launched as an emerging oncology company focused orphan drugs for the treatment of pediatric cancers. Its current candidate is preparing for a phase I/IIa trial for the treatment of relapsed or refractory medulloblastoma – a rare, life-threatening brain tumor that mainly affects children.
Glioblastoma tumors were successfully infiltrated by investigational chimeric antigen receptor (CAR) therapy with an acceptable safety profile, according to phase 1 study results presented at the American Association for Cancer Research 2016 Annual Meeting.
A leading medical device company in the field of nanomedicine focused on oncology, today announced that Vivantes Friedrichshain, Department of Neurosurgery has initiated Commercial NanoTherm(TM) Treatments for brain cancer.
Optune is an FDA-approved portable, noninvasive device that delivers Tumor Treating Fields (TTFields) therapy to patients with newly diagnosed and recurrent glioblastoma.
A key player in brain tumor formation has been found that may lead to new therapies for a deadly and incurable cancer. The study is the first to show that a protein called OSMR (Oncostatin M Receptor) is required for glioblastoma tumours to form.
Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.
In the study, researchers found that people who regularly took aspirin had a nearly 34 percent lower risk of a type of brain tumor called a glioma, compared with people who didn't take aspirin regularly.
Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors researchers reported.
Research demonstrated a significant enough link between children having acquired chickenpox and their reduced likelihood of developing brain cancer that the results shouldn’t be dismissed as coincidence.
University of Florida experts examined mice models of human glioblastoma and discovered that a high-fat, low carbohydrate diet can help to stall the development of tumor cells and increase lifespans by 50 percent.
It is more like a sensor that surgeons can run over tissue matter and supposedly in half a second, it will be able to tell the surgeon which part of the tissue is tumorous and which part isn’t, so like we said, it helps reduce the rate of errors.
Be prepared for goosebumps!
If you want to see more on this, watch this 10:39 video on this amazing relationship between player and patient.
Scientists discovered a compound in blue-green algae called coibamide A
It cuts off cancer cells' communication with blood vessels and other cells.
They studied 251 patients -- half of whom underwent radiation treatments only, half underwent both radiation and chemotherapy treatments. The researchers learned that those who received both treatments lived an average of 5 1/2 years longer, and many are doing well 10 years later.
A new test can help doctors pinpoint what is driving the tumor and better target their treatment early on. This time, doctors took a small sample of his tumor and ran it through cutting-edge molecular testing designed to pick up genetic mutations. It’s called Glio Seq.
Much cancer research is focused on immunotherapy rather than chemotherapy for treatment. Immunotherapy stimulates the body’s own immune system to fight a malignancy and has numerous advantages over chemotherapy.
Removing a brain tumor is a delicate task, if not done properly it can have catastrophic consequences, such as brain damage, motor impairment or failure in controlling a vital organ function. In order to make this work more precise, a "smart scalpel" that determines whether an area is healthy or tumorous.
The study shows that in glioblastoma (GBM), the essential amino acids methionine and tryptophan are abnormally metabolized due to the loss of key enzymes in GBM cells.
When doctors detect a tumor the next course of action is typically surgery, but when it's a brain tumor, surgery isn't always an option. So what can you do? Well doctors at Avera will soon be able to take the cutting out of brain surgery.
Diffusion Pharmaceuticals Inc. CEO David Kalergis. lays out Diffusion’s plan for pivotal development of its treatment for primary brain cancer.
Medical team experimented with MRI techniques to track “natural killer” cells after they were injected with fluorine-19, a non-radioactive, naturally occurring isotope.
Doctor believes with an as-yet-to-be-determined combination of immunotherapy and precision medicine, brain cancer researchers may finally make some headway against this long intractable problem.
A next-generation immunotherapy may offer hope for treating high-grade glioma. While dendritic cell-based immunotherapy is known to be promising, this study combined dendritic cell immunotherapy with immunogenic cell death.
When doctors diagnosed a 4-year-old doctor with brain tumors, they told her parents there was little hope. But then they all decided to take the only chance they had. 3 ago, no one knew if Allison would ever walk to the bus stop. Now, it's hard keeping up with her.
What if before initiating treatment, they could go a step further and use a mini-model of the human body to see how each patient's actual tumor responds to the drugs and learn if and where the tumor is likely to spread?
A cap fitted with arrays of electrodes and worn on the head all day and all night, Optune uses alternating electric fields to disrupt the tumor in the vital process of cell division. If the cells don't divide, the tumor doesn't grow.
Scientists at Memorial Sloan Kettering Cancer Center’s Kircher laboratory have developed a biomarker that adsorbs exclusively to the surface of cancerous cells in brain tumors. The technology can be used for therapeutic purposes (surgery) as well as diagnostics, even in the early stages of cancer.
Researchers have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast growing type of pediatric brain cancer.
Scientists at the nonprofit Translational Genomics Research Institute (TGen) have identified a drug called propentofylline, or PPF, that could help patients suffering from glioblastoma multiforme (GBM), a deadly form of brain cancer.
Opdivo is a new class of medicine called an immune-oncology drug. What’s unique about the drug, and as many as 100 more in pharmaceutical pipelines that are expected to work in similar ways, is how they fight cancer cells.
Researchers believe they may have found a way to turn a patient’s skin cells into cancer killing cells, leading to a “groundbreaking discovery” for brain cancer patients.
Stem cells from a patient’s own skin may help fight the most common and most aggressive forms of brain cancer, according to University of North Carolina at Chapel Hill researchers who tested the theory in a lab.
Jimmy Carter announced that his doctors are stopping his immunotherapy treatment called pembrolizumab after they saw no signs of tumors over a period of three months.
Elekta announced that its Leksell Gamma Knife® Icon™, the most precise stereotactic radiosurgery (SRS) system currently available, was used for the first time in the US on 3/1 at Sutter Medical Center to treat a metastatic brain tumor.
Moffitt Cancer Center researchers recently reported that expression of the protein BIRC3 is associated with poor survival and recurrent disease in GBM patients; and therefore may be a good therapeutic target.
Clinical outcomes were similar with the Gamma Knife Perfexion (Elekta AB) and RapidArc (Varian Medical Systems), a linear accelerator (LINAC)-based volumetric modulated arc therapy (VMAT).
Scientists from KU Leuven in Belgium say they have shown that next-generation cell-based immunotherapy may offer new hope in the fight against brain cancer.
Children with brain cancer may soon get some help from mice with the same disease. In a new paper in Science Translational Medicine, the U-M team describes how they developed a novel brain tumor model in mice.
USC School of Pharmacy researchers who led the study on mice found that the drugs stifle the growth of brain cancer, glioma or glioblastoma, by suppressing the enzyme “monoamine oxidase A,” which affects the release of emotional brain chemicals.
Early stages of testing a vaccine that targets EGFRvIII — a genetic abnormality of the epidermal growth factor receptor (EGFR) that occurs in about one-third of glioblastoma patients and that’s associated with tumor growth and resistance to therapy.
Antidepressants can shrink and stunt cancerous brain tumors that are otherwise difficult to treat, an international team of researchers has found.
Gamma Knife and RapidArc offer different strengths, they are equally effective at eradicating cancer in the brain. The Gamma Knife was slightly more effective than RapidArc at focusing the beam of radiation and RapidArc offered much quicker treatment.
VBL Therapeutics is moving to the final stage of clinical trials for its leading product, VB-111, for the treatment of brain tumor patients. The trial will compare VBL's drug used in combination with oncological drug Avastin with the use of Avastin by itself in the treatment of recurring glioblastoma.
Virtual reality is becoming increasingly useful when it comes to the medical field. Physicians used a VR headset to map a patient's brain during surgery to remove a tumor late last month.
Two small structural elements, called decorin and lumican, could be decisive in the development of a resistance to the drugs currently used for treating glioblastoma multiforme, such as temozolamide.
A team of researchers have identified a common molecular alteration in glioblastoma. They observed that the cells of this type of tumor harbor a common intrinsic defect that prevents them from degrading their genetic material during apoptosis, the most important form of programmed cell death induced by radiotherapy and chemotherapy.
The low-carb, high-fat ketogenic diet can replace chemotherapy and radiation for even the deadliest of cancers, said Dr. Thomas Seyfried, a leading cancer researcher and professor at Boston College.
A new two-drug combination, currently in use in the clinical trials, might help people diagnosed with glioblastoma to fight the disease. The researchers are using a combination of drugs to disrupt the cellular process cancer cells use to hide from the immune system.
Despite the letdown of prior research, the future looks bright for immunotherapeutics and novel targeted therapy approaches for patients with gliomas.
The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders.
As more and more health care institutions consider the viability of providing proton therapy to their patients, new research has emerged to further cement the notion that, where young lives are concerned, there is no better option currently available.
A powerful, three-way mechanism by which a mutation drives the growth of childhood brain cancers, was discovered by scientists. The team hopes the discovery will lead to better methods for diagnosing and treating these cancers, which cannot always be cured with surgery.
While mapping vessels in tumours has proven a challenge, researchers have now developed a combined MRI and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible.
Proton radiation is more "precisely focused" than photon radiation, which lessens the chance healthy tissue surrounding the target area will be affected.
When comparing numbers regarding IQ loss over extended periods of time, PBRT showed a decline of 0.7 IQ points per year while the traditional photon radiation treatment was marked at 1.1 points per year.
A comprehensive analysis of the molecular characteristics of explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
Thanks to advances in science, however, there’s now a handheld microscope that can look at the brain on a cellular level while inside the operating room, and allow surgeons to decide more confidently where to stop cutting.
A new study may explain why some patients diagnosed with slow-growing, low-grade tumors end up quickly succumbing to the disease while others with supposedly more aggressive high-grade tumors survive for many years.
A local brain cancer specialist believes more lives could be saved if doctors took a closer look at individual tumors, which is the game-changing approach that saved one teen in Agoura Hills.
The iMRI is a unique set-up that melds the sterile environment of an operating room with the imaging technology of an MRI machine. It allows neurosurgeons the ability to scan patients during surgery and see a detailed image of their progress in real time.
The idea was to find a way to model all the mutations of a particular glioblastoma simultaneously, with the goal of using data from real tumors to find targets that can be effectively attacked.
The iMRI allows neurosurgeons to fully evaluate brain imaging during surgery and to image a patient while in the operating room, which allows a surgeon to ‘see’ if all the cancer has been removed before leaving the OR.
Gleostine® 5 mg capsules has been approved by the FDA . It is approved for use as a single agent treatment or with other approved chemotherapeutic agents to treat both primary and metastatic brain tumors.
"As a truly minimally invasive surgery, I anticipate that the quality of life of the laser-treated patients to be significantly improved relative to conventional surgeries where large incisions are made and significant portions of skull are removed."
While most high school students look forward to spending their summer vacations catching up on some well-deserved rest, one Cotter senior spent two weeks of his summer working on computer coding software that would aid surgeons operating on patients with brain tumors.
Dr. Tsung says, "It allows us to scan the patient as we're operating - to define what we're taking out, how much we removed, and to protect critical areas of the brain… The patient remains sterile, the brain remains open as we run into the scanner and we roll them back out."
Scientists have identified a protein interaction that is a hallmark of an aggressive subtype of medulloblastoma and that may provide a new treatment strategy. The research appears today in the scientific journal Cancer Cell.
Stem cells found in the tumors are responsible for making glioblastoma hard to treat because they are drug-resistant and self-renewing. This study is the first to focus on how the extracellular matrix surrounding the tumor affects the development of cancer stem-like cells in a 3D microenvironment.
Cells, when dividing, utilize and enzyme called Dicer. This helps cells repair any DNA damage that occurs when errors are made as cells copy genetic material again and again. Scientists have used this knowledge as a new technique to kill rapidly dividing, cancerous cells in the brain.
For patients undergoing surgery for low-grade glioma, who must be "awake" to facilitate mapping, hypnosis allows surgeons to safely remove the tumor up to functional boundaries, according to a first-of-its-kind study.
Scientists at the Salk Institute have discovered a key to how glioblastoma multiformetumor cells proliferate so quickly --and ways to turn this engine of tumor growth into a target for cancer treatment. The late Senator Ted Kennedy succumbed to this disease in just over a year.
An international research team has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme’s potential to become a therapeutic target for future cancer drugs.
A technique which replaces general anesthetics was used on 37 patients undergoing surgery to remove brain tumors. Though there's been little science to back up hypnotherapy, the authors conclude that their small study's success suggests hypnosis could be a viable tool to help sedate patients during delicate brain surgery.
Progression-free and overall survival were prolonged with maintenance therapy involving tumor-treating fields (TTFields) and chemotherapy in patients with a brain tumor who had completed standard chemoradiation, according to early research findings published in JAMA.
A noninvasive, low-cost blood test was developed to help doctors diagnose some types of malignant childhood tumor Cancer. The test could enable clinicians to monitor treatment effectiveness without exposing patients to repeated doses of radiation.
The surgeons behind the study believe that this research proves that “hypnosedation” can be a valuable tool for patients with advanced brain cancers.
Patients receive injections – directly at the tumor site – of immune cells genetically modified to recognize certain markers on cancer cells.
A study of gliomas found that DNA structure was disrupted, allowing separate segments to merge and activate a growth gene. An existing chemotherapy drug may fix that.
Scientists say they have developed a novel 3D cell culture technique that allows brain tumor growth to be studied directly and without the need for complex experiments using live animals.